Recommendations for observational studies of comorbidity in multiple sclerosis

Ruth Ann Marrie, Aaron Miller, Maria Pia Sormani, Alan Thompson, Emmanuelle Waubant, Maria Trojano, Paul O'Connor, Kirsten Fiest, Nadia Reider, Stephen Reingold, Jeffrey A. Cohen, Giancarlo Comi

Research output: Contribution to journalReview article

Abstract

Objective: To reach consensus about the most relevant comorbidities to study in multiple sclerosis (MS) with respect to incidence, prevalence, and effect on outcomes; review datasets that may support studies of comorbidity in MS; and identify MS outcomes that should be prioritized in such studies. Methods: We held an international workshop to meet these objectives, informed by a systematic review of the incidence and prevalence of comorbidity in MS, and an international survey regarding research priorities for comorbidity. Results: We recommend establishing age- and sex-specific incidence and prevalence estimates for 5 comorbidities (depression, anxiety, hypertension, hyperlipidemia, and diabetes); evaluating the effect of 7 comorbidities (depression, anxiety, hypertension, diabetes, hyperlipidemia, chronic lung disease, and autoimmune diseases) on disability, quality of life, brain atrophy and other imaging parameters, health care utilization, employment, and mortality, including age, sex, race/ethnicity, socioeconomic status, and disease duration as potential confounders; harmonizing study designs across jurisdictions; and conducting such studies worldwide. Ultimately, clinical trials of treating comorbidity in MS are needed. Conclusion: Our recommendations will help address knowledge gaps regarding the incidence, prevalence, and effect of comorbidity on outcomes in MS.
Original languageEnglish
Pages (from-to)1446 - 1453
Number of pages8
JournalNeurology
Volume86
Issue number15
DOIs
Publication statusPublished - Apr 12 2016

Fingerprint

Multiple Sclerosis
Observational Studies
Comorbidity
Incidence
Hyperlipidemias
Anxiety
Patient Acceptance of Health Care
Depression
Hypertension
Social Class
Lung Diseases
Autoimmune Diseases
Atrophy
Consensus
Chronic Disease
Quality of Life
Clinical Trials
Education
Mortality
Brain

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

Marrie, R. A., Miller, A., Sormani, M. P., Thompson, A., Waubant, E., Trojano, M., ... Comi, G. (2016). Recommendations for observational studies of comorbidity in multiple sclerosis. Neurology, 86(15), 1446 - 1453. https://doi.org/10.1212/WNL.0000000000002474

Recommendations for observational studies of comorbidity in multiple sclerosis. / Marrie, Ruth Ann; Miller, Aaron; Sormani, Maria Pia; Thompson, Alan; Waubant, Emmanuelle; Trojano, Maria; O'Connor, Paul; Fiest, Kirsten; Reider, Nadia; Reingold, Stephen; Cohen, Jeffrey A.; Comi, Giancarlo.

In: Neurology, Vol. 86, No. 15, 12.04.2016, p. 1446 - 1453.

Research output: Contribution to journalReview article

Marrie, RA, Miller, A, Sormani, MP, Thompson, A, Waubant, E, Trojano, M, O'Connor, P, Fiest, K, Reider, N, Reingold, S, Cohen, JA & Comi, G 2016, 'Recommendations for observational studies of comorbidity in multiple sclerosis', Neurology, vol. 86, no. 15, pp. 1446 - 1453. https://doi.org/10.1212/WNL.0000000000002474
Marrie RA, Miller A, Sormani MP, Thompson A, Waubant E, Trojano M et al. Recommendations for observational studies of comorbidity in multiple sclerosis. Neurology. 2016 Apr 12;86(15):1446 - 1453. https://doi.org/10.1212/WNL.0000000000002474
Marrie, Ruth Ann ; Miller, Aaron ; Sormani, Maria Pia ; Thompson, Alan ; Waubant, Emmanuelle ; Trojano, Maria ; O'Connor, Paul ; Fiest, Kirsten ; Reider, Nadia ; Reingold, Stephen ; Cohen, Jeffrey A. ; Comi, Giancarlo. / Recommendations for observational studies of comorbidity in multiple sclerosis. In: Neurology. 2016 ; Vol. 86, No. 15. pp. 1446 - 1453.
@article{56c4e81c295846e0adb56a3a72129591,
title = "Recommendations for observational studies of comorbidity in multiple sclerosis",
abstract = "Objective: To reach consensus about the most relevant comorbidities to study in multiple sclerosis (MS) with respect to incidence, prevalence, and effect on outcomes; review datasets that may support studies of comorbidity in MS; and identify MS outcomes that should be prioritized in such studies. Methods: We held an international workshop to meet these objectives, informed by a systematic review of the incidence and prevalence of comorbidity in MS, and an international survey regarding research priorities for comorbidity. Results: We recommend establishing age- and sex-specific incidence and prevalence estimates for 5 comorbidities (depression, anxiety, hypertension, hyperlipidemia, and diabetes); evaluating the effect of 7 comorbidities (depression, anxiety, hypertension, diabetes, hyperlipidemia, chronic lung disease, and autoimmune diseases) on disability, quality of life, brain atrophy and other imaging parameters, health care utilization, employment, and mortality, including age, sex, race/ethnicity, socioeconomic status, and disease duration as potential confounders; harmonizing study designs across jurisdictions; and conducting such studies worldwide. Ultimately, clinical trials of treating comorbidity in MS are needed. Conclusion: Our recommendations will help address knowledge gaps regarding the incidence, prevalence, and effect of comorbidity on outcomes in MS.",
author = "Marrie, {Ruth Ann} and Aaron Miller and Sormani, {Maria Pia} and Alan Thompson and Emmanuelle Waubant and Maria Trojano and Paul O'Connor and Kirsten Fiest and Nadia Reider and Stephen Reingold and Cohen, {Jeffrey A.} and Giancarlo Comi",
year = "2016",
month = "4",
day = "12",
doi = "10.1212/WNL.0000000000002474",
language = "English",
volume = "86",
pages = "1446 -- 1453",
journal = "Neurology",
issn = "0028-3878",
publisher = "Lippincott Williams and Wilkins",
number = "15",

}

TY - JOUR

T1 - Recommendations for observational studies of comorbidity in multiple sclerosis

AU - Marrie, Ruth Ann

AU - Miller, Aaron

AU - Sormani, Maria Pia

AU - Thompson, Alan

AU - Waubant, Emmanuelle

AU - Trojano, Maria

AU - O'Connor, Paul

AU - Fiest, Kirsten

AU - Reider, Nadia

AU - Reingold, Stephen

AU - Cohen, Jeffrey A.

AU - Comi, Giancarlo

PY - 2016/4/12

Y1 - 2016/4/12

N2 - Objective: To reach consensus about the most relevant comorbidities to study in multiple sclerosis (MS) with respect to incidence, prevalence, and effect on outcomes; review datasets that may support studies of comorbidity in MS; and identify MS outcomes that should be prioritized in such studies. Methods: We held an international workshop to meet these objectives, informed by a systematic review of the incidence and prevalence of comorbidity in MS, and an international survey regarding research priorities for comorbidity. Results: We recommend establishing age- and sex-specific incidence and prevalence estimates for 5 comorbidities (depression, anxiety, hypertension, hyperlipidemia, and diabetes); evaluating the effect of 7 comorbidities (depression, anxiety, hypertension, diabetes, hyperlipidemia, chronic lung disease, and autoimmune diseases) on disability, quality of life, brain atrophy and other imaging parameters, health care utilization, employment, and mortality, including age, sex, race/ethnicity, socioeconomic status, and disease duration as potential confounders; harmonizing study designs across jurisdictions; and conducting such studies worldwide. Ultimately, clinical trials of treating comorbidity in MS are needed. Conclusion: Our recommendations will help address knowledge gaps regarding the incidence, prevalence, and effect of comorbidity on outcomes in MS.

AB - Objective: To reach consensus about the most relevant comorbidities to study in multiple sclerosis (MS) with respect to incidence, prevalence, and effect on outcomes; review datasets that may support studies of comorbidity in MS; and identify MS outcomes that should be prioritized in such studies. Methods: We held an international workshop to meet these objectives, informed by a systematic review of the incidence and prevalence of comorbidity in MS, and an international survey regarding research priorities for comorbidity. Results: We recommend establishing age- and sex-specific incidence and prevalence estimates for 5 comorbidities (depression, anxiety, hypertension, hyperlipidemia, and diabetes); evaluating the effect of 7 comorbidities (depression, anxiety, hypertension, diabetes, hyperlipidemia, chronic lung disease, and autoimmune diseases) on disability, quality of life, brain atrophy and other imaging parameters, health care utilization, employment, and mortality, including age, sex, race/ethnicity, socioeconomic status, and disease duration as potential confounders; harmonizing study designs across jurisdictions; and conducting such studies worldwide. Ultimately, clinical trials of treating comorbidity in MS are needed. Conclusion: Our recommendations will help address knowledge gaps regarding the incidence, prevalence, and effect of comorbidity on outcomes in MS.

UR - http://www.scopus.com/inward/record.url?scp=84964872986&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84964872986&partnerID=8YFLogxK

U2 - 10.1212/WNL.0000000000002474

DO - 10.1212/WNL.0000000000002474

M3 - Review article

VL - 86

SP - 1446

EP - 1453

JO - Neurology

JF - Neurology

SN - 0028-3878

IS - 15

ER -